Montreal / August 21, 2025 - NexPlasmaGen is pleased to announce that Mr. Suman Mallick has joined NexPlasmaGen board! Suman Mallick is a Managing Director at Keystone National Group, where is the co-head of the Financial Assets practice and manages a portfolio of private credit investments....
Montreal / July 24, 2025 – NexPlasmaGen is proud to announce that it has secured a patent in South Korea to protect its Convertible Plasma Jet (CPJ) technology for breast cancer treatment. The patent application number in the Republic of Korea is No. 10-2022-7001947. This patent...
Montreal / April 25, 2025 – Clinical researchers at the University of Montreal Hospital Center (CHUM) have published in the journal BMC Cancer the clinical protocol for human safety trials initiated at CHUM with NexPlasmaGen medical technology for the treatment of breast cancer. The published article can...
Montreal / October 06, 2023 - NexPlasmaGen received a financial support of $219,500 from Quebec's Ministère de l'économie, de l'innovation et de l'énergie (MEIE), the National Research Council of Canada (NRC), the Université de Montréal (UdM) and the Mouvement des accélérateurs d'innovation du Québec (MAIN)...